AOA Dx
YC S21 · Active · Blood Test for Early Detection of Ovarian Cancer
Competitors
| Company | Category | Status | Program |
|---|---|---|---|
| Other | Active | YCS18 | |
| AI | Active | YCS17 | |
| Other | Not stated | EF2019 | |
| Other | Acquired | YCW16 | |
| Other | Active | YCW17 |
Adjacent
| Company | Category | Status | Program |
|---|---|---|---|
| AI | Active | YCS23 | |
| Other | Inactive | YCS16 | |
| AI | Not stated | EF2016 | |
| Other | Active | YCS22 | |
| Other | Active | YCW15 |
Also from S21
All of S21About AOA Dx
AOA Dx is developing the next frontier in early-stage cancer detection for women through our pioneering work in glycolipids and proprietary biomarker technology.
- YC batch
- S21 · Summer 2021
- Status, per YC
- Active
- Category
- Other
- Team size
- 25
- Location
- Denver, CO, USA; Cambridge, MA, USA
- Checked
- 1h ago
YC tags: Healthcare, Diagnostics, Women's Health
AOA Dx: questions
Which YC batch was AOA Dx in?
AOA Dx was in Y Combinator's Summer 2021 batch (S21).
Is AOA Dx still active?
Y Combinator lists AOA Dx as active.
Where is AOA Dx based?
AOA Dx lists Denver, CO, USA; Cambridge, MA, USA as its location on YC's directory.
Sources: each program's public company list, read twice a week. Not affiliated with Y Combinator or any other program. Logos via logo.dev; trademarks belong to their owners.